Amplification of HER2/neu gene or otherwise overexpression of the human epidermal growth factor receptor 2 (HER2) is found in approximately 15–20% of breast cancers [2] and has been classically associated with an aggressive clinical course and poor outcomes [3]. This evidence concerns the gene ERBB2 and breast cancer.